Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity

Journal of Clinical Investigation

Volumn 96, Issue 3, 1995, Pages 1389-1394

  Roselaar, Simon E ^a   Schonfeld, Gustav ^a   Daugherty, Alan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; autoantibodies; cyclosporin A; Immunosuppression; T lymphocytes

Indexed keywords

AUTOANTIBODY; CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE;

ANIMAL MODEL; ANTIBODY TITER; AORTA ATHEROSCLEROSIS; ARTICLE; CELLULAR IMMUNITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GRAFT SURVIVAL; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RABBIT; SKIN ALLOGRAFT; T LYMPHOCYTE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029092584     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118174     Document Type: Article

References (48)

1. Emeson, E. E., and A. L. Robertson. 1988. T-lymphocytes in aortic and coronary intimas: their potential role in atherogenesis. Am. J. Pathol. 130:369-376.
2. Hansson, G. K., L. Jonasson, B. Lojsthed, S. Stemme, O. Kocher, and G. Gabbiani. 1988. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis. 72:135-141.
3. Katsuda, S., H. C. Boyd, C. Fligner, R. Ross, and A. M. Gown. 1992. Human atherosclerosis. 3. Immunocytochemical analysis of the cell composition of lesions of young adults. Am. J. Pathol. 140:907-914.
4. Jonasson, L., J. Holm, O. O. Skalli, B. Bondjers, and G. K. Hansson. 1986. Regional accumulation of T cells, macrophages and smooth muscle cells in human atherosclerotic plaques. Arterioscler. Thromb. 6:131-138.
5. Hansson, G. K., P. S. Seifert, G. Olsson, and G. Bondjers. 1991. Immunohistochemical detection of macrophages and T-lymphocytes in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler. Thromb. 11:745-750.
6. Munro, J. M., J. D. Van der Walt, C. S. Munro, J. A. C. Chalmers, and E. L. Cox. 1987. An immunohistochemical analysis of human aortic fatty streaks. Hum. Pathol. 18:375-380.
7. Xu, Q., G. Oberhuber, M. Gruschwitz, and G. Wick. 1990. Immunology of atherosclerosis: cellular composition and major histocompatability complex class II antigen expression in aortic intima, fatty streaks and atherosclerotic plaques in young and aged human specimens. Clin. Immunol. Immunopathol. 56:344-359.
8. Stemme, S., J. Holm, and G. K. Hansson. 1992. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and integrin VLA-1. Arterioscler. Thromb. 12:206-211.
9. Stemme, S., L. Rymo, and G. K. Hansson. 1991. Polyclonal origin of lymphocytes-T in human atherosclerotic plaques. Lab. Invent. 65:654-660.
10. Stemme, S., and G. K. Hansson. 1994. Immune mechanisms in atherosclerosis. Coronary Artery Dis. 5:216-222.
11. Elliot, J. F., Y. Lin, S. B. Mizel, R. C. Bleakley, D. G. Harnish, and V. T. Paetkau. 1984. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science. 226:1439-1441.
12. Granelli-Piperno, A., K. Inaba, and R. M. Steinman. 1984. Stimulation of lymphokine release from T lymphoblasts. J. Exp. Med. 160:1792-1802.
13. Di Padova, F. E. 1989. Pharmacology of cyclosporine (Sandimmune) V. Pharmacological effects on immune function: in vitro studies. Pharmacol Rev. 41:373-405.
14. Shah, A. K., R. C. Brundage, A. Gratwohl, and R. J. Sawchuk. 1992. Pharmacokinetic model for the subcutaneous absorption of cyclosporin in the rabbit during chronic treatment. J. Pharmaceut. Sci. 81:491-495.
15. Daugherty, A., and D. L. Rateri. 1991. Heterogeneity of very low density lipoprotein fractions: Factors influencing the ability of specific subfractions to modulate cholesterol metabolism in macrophages in vitro. Coron. Artery Dis. 2:775-787.
16. Daugherty, A., B. S. Zweifel, and G. Schonfeld. 1991. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. Br. J. Pharmacol. 103:1013-1018.
17. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and characterization. Can. J. Physiol. Biochem. 37:911-916.
18. Ishikawa, T. T., J. MacGee, A. Morrison, and C. J. Glueck. 1974. Quantitative analysis of cholesterol in 5 to 20 μl of plasma. J. Lipid Res. 15:286-291.
19. Haberland, M. E., Fogelman A. M., and P. A. Edwards. 1982. Specificity of receptor-mediated recognition of malondialdehyde modified low density lipoproteins. Proc. Natl. Acad. Sci. USA. 79:1712-1726.
20. Handschumacher, R. E., M. W. Harding, J. Rice, R. J. Drugge, and D. W. Speicher. 1984. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (Wash. DC). 226:544-547.
21. Koletsky, A. J., M. W. Harding, and R. E. Handschumacher. 1986. Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J. Immunol. 137:1054-1059.
22. Chan, B. B. K., J. A. Kern, T. L. Flanagan, I. L. Kron, and C. G. Tribble. 1992. Effect of in vivo cyclosporine administration on endothelium-dependent responses in isolated vascular rings. Circulation. 86:SII-295-SII-299.
23. Roullet, J.-P., H. Xue, D. A. McCarron, S. Holcomb, and W. M. Bennett. 1994. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J. Clin. Invest. 93:2244-2250.
24. Garr, M. D., and M. S. Paller. 1990. Cyclosporine augments renal but not systemic vascular reactivity. Am. J. Physiol. 258:F211-F217.
25. Textor, S. C., L. Smith-Powell, and T. Telles. 1990. Altered pressor responses to norepinephrine and ANGII during cyclosporin A administration to conscious rats. Am. J. Physiol. 258:H854-H860.
26. Rayat, G., R. Yatscoff, R. Silverman, and R. McKenna. 1993. A comparison of the immunosuppressive effects of cyclosporin A and cyclosporin G in vivo and in vitro. Transplantation (Baltimore). 55:623-626.
27. McMurray, H. F., S. Parthasarathy, and D. Steinberg. 1993. Oxidatively modified low density lipoprotein is a chemoattractant for human T-lymphocytes. J. Clin. Invest. 92:1004-1008.
28. Daugherty, A., and S. E. Roselaar. 1995. Lipoprotein oxidation as a mediator of atherogenesis: Insights from pharmacological studies. Cardiovasc. Res. 29:297-311.
29. Sakaguchi, S., and N. Sakaguchi. 1989. Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. J. Immunol. 142:471-480.
30. Wick, G., P. Müller, and S. Schwarz. 1982. Effect of cyclosporin A on spontaneous autoimmune thyroiditis of obese strain chickens. Eur. J. Immunol. 12:877-881.
31. Bucy, R. P., X. X. Xu, J. Li, and G. Huang. 1993. Cyclosporin A-induced autoimmune disease in mice. J. Immunol. 151:1039-1050.
32. Jonasson, L., J. Holm, and G. K. Hansson. 1988. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc. Natl. Acad. Sci. USA. 85:2303-2306.
33. Ferns, G., M. Reidy, and R. Ross. 1990. Vascular effects of cyclosporine A in vivo and in vitro. Am. J. Pathol. 137:403-413.
34. Hansson, G. K., J. Holm, S. Holm, Z. Fotev, H. J. Hedrich, and I. Fingerle. 1991. T lymphocytes inhibit the vascular response to injury. Proc. Natl. Acad. Sci. USA. 88:10530-10534.
35. Hansson, G. K., and J. Holm. 1991. Interferon-γ Inhibits arterial stenosis after injury. Circulation. 84:1266-1272.
36. Emeson, E. E., and M. L. Shen. 1993. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am. J. Pathol. 142:1906-1915.
37. Fyfe, A. I., J. H. Qiao, and A. J. Lusis. 1994. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J. Clin. Invest. 94:2516-2520.
38. Qiao, J. H., P. Z. Xie, M. C. Fishbein, J. Kreuzer, T. A. Drake, L. L. Demer, and A. J. Lusis. 1994. Pathology of atheromatous lesions in inbred and genetically engineered mice - Genetic determination of arterial calcification. Arterioscler. Thromb. 14:1480-1497.
39. Wilson, A. C., R. G. Schaub, R. C. Goldstein, and P. T. Kuo. 1990. Suppression of aortic atherosclerosis in cholesterol-fed rabbits by purified rabbit interferon. Arteriosclerosis. 10:208-214.
40. Kuo, P. T., A. C. Wilson, Goldstein R. C., and R. G. Schaub. 1984. Suppression of experimental atherosclerosis in rabbits by interferon-inducing agents. J. Am. Coll. Cardiol. 3:129-134.
41. Ylä-Herttuala, S., W. Palinski, S. W. Butler, S. Picard, D. Steinberg, and I. L. Witztum. 1994. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14:32-40.
42. Palinski, W., M. E. Rosenfeld, S. Ylä-Herttuala, G. C. Gurtner, S. A. Socher, S. W. Butler, S. Parthasarathy, T. E. Carew, D. Steinberg, and J. L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vitro. Proc. Natl. Acad. Sci. USA. 86:1372-1376.
43. Palinski, W., V. A. Ord, A. S. Plump, J. L. Breslow, D. Steinberg, and J. L. Witztum. 1994. Apo-E deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation specific epitopes in lesions and high titres of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14:605-616.
44. Salonen, J. T., S. Ylä-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssonen, W. Palinski, and J. L. Witztum. 1992. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:883-887.
45. Palinski, W., E. Miller, and J. L. Witztum. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA. 92:821-825.
46. Hansson, G. K., J. Holm, and L. Jonasson. 1989. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135:169-175.
47. Fogelman, A. M., I. Seager, M. E. Haberland, M. Hokom, R. Tanaka, and P. A. Edwards. 1982. Lymphocyte-conditioned medium protects human monocyte-macrophages from cholesteryl ester accumulation. Proc. Natl. Acad. Sci. USA. 79:922-926.
48. Geng, Y. J., and G. K. Hansson. 1992. Interferon-γ inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J. Clin. Invest. 89:1322-1330.